Celyad Oncology (LTS:0QFK) Total Equity: €2.44 Mil (As of Dec. 2025)


LTS:0QFK Celyad Oncology SA LTS:0QFK
13 GF Score
Price €0.23
GF Value €0.67
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Celyad Oncology Total Equity?

Celyad Oncology LTS:0QFK 13 Total Equity is €2.44 Mil as of Dec. 2025. GuruFocus rates LTS:0QFK with a GF Score™ of 13/100 and a GF Value™ of €0.67 (Possible Value Trap). The stock has 6 warning signs investors should review.

Celyad Oncology's total equity for the quarter that ended in Dec. 2025 was €2.44 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Celyad Oncology Total Equity Historical Data

* Premium members only.

The historical data trend for Celyad Oncology's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celyad Oncology Total Equity Chart

Celyad Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.64 4.32 6.30 0.51 2.44

Celyad Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.30 3.27 0.51 -3.10 2.44
LTS:0QFK
13GF Score
Celyad Oncology SA LTS:0QFK
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celyad Oncology Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Celyad Oncology's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=4.298-1.862
=2.44

Celyad Oncology's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=4.298-1.862
=2.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €2.44 Mil mean?
Celyad Oncology (LTS:0QFK) has a Total Equity of €2.44 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Celyad Oncology and its competitors.
Is Celyad Oncology's Total Equity too high?
Celyad Oncology's current Total Equity is €2.44 Mil. Overall, Celyad Oncology has a GF Score™ of 13/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Total Equity compare to VRTX and REGN?
Celyad Oncology's Total Equity of €2.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Celyad Oncology and its competitors. Celyad Oncology's current Total Equity is €2.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (LTS:0QFK) is currently considered Possible Value Trap. The stock's GF Value™ is €0.67, compared to a current price of €0.23 — trading 65% below its estimated fair value. The current Total Equity is €2.44 Mil. Celyad Oncology's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Celyad Oncology (LTS:0QFK), the current Total Equity is €2.44 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celyad Oncology (LTS:0QFK) Overvalued in 2026?

Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued. The current stock price of €0.23 is trading 65% below its estimated GF Value™ of €0.67. GuruFocus considers Celyad Oncology to be Possible Value Trap.

Key valuation signals for LTS:0QFK:

  • Total Equity: €2.44 Mil
  • GF Value™: €0.67 vs. price of €0.23 (65% below fair value)
  • GF Score™: 13/100 with 6 warning signs

No single metric tells the full story. See the LTS:0QFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celyad Oncology Business Description

Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
13GF Score

Get the complete analysis for LTS:0QFK

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.23
Price
€0.67
GF Value